Guiding Drug Repositioning for Cancers Based on Drug Similarity Networks

Drug repositioning aims to discover novel clinical benefits of existing drugs, is an effective way to develop drugs for complex diseases such as cancer and may facilitate the process of traditional drug development. Meanwhile, network-based computational biology approaches, which allow the integration of information from different aspects to understand the relationships between biomolecules, has been successfully applied to drug repurposing. In this work, we developed a new strategy for network-based drug repositioning against cancer. Combining the mechanism of action and clinical efficacy of the drugs, a cancer-related drug similarity network was constructed, and the correlation score of each drug with a specific cancer was quantified. The top 5% of scoring drugs were reviewed for stability and druggable potential to identify potential repositionable drugs. Of the 11 potentially repurposable drugs for non-small cell lung cancer (NSCLC), 10 were confirmed by clinical trial articles and databases. The targets of these drugs were significantly enriched in cancer-related pathways and significantly associated with the prognosis of NSCLC. In light of the successful application of our approach to colorectal cancer as well, it provides an effective clue and valuable perspective for drug repurposing in cancer.

[1]  Geng Tian,et al.  Computational drug repositioning using similarity constrained weight regularization matrix factorization: A case of COVID‐19 , 2022, Journal of cellular and molecular medicine.

[2]  A. Goede,et al.  SuperPred 3.0: drug classification and target prediction—a machine learning approach , 2022, Nucleic Acids Res..

[3]  Ning Wang,et al.  CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives , 2022, Theranostics.

[4]  H. Kume,et al.  Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach , 2022, EBioMedicine.

[5]  Jianzhen Xu,et al.  Computational Drug Repurposing Based on a Recommendation System and Drug–Drug Functional Pathway Similarity , 2022, Molecules.

[6]  J. Mazières,et al.  Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Xiangxiang Zeng,et al.  A weighted bilinear neural collaborative filtering approach for drug repositioning , 2022, Briefings Bioinform..

[8]  D. Hanahan.  Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[9]  Seyedeh Shaghayegh Sadeghi,et al.  A network-based drug repurposing method via non-negative matrix factorization , 2021, Bioinform..

[10]  Shudong Wang,et al.  Network‐Based Approaches for Drug Repositioning , 2021, Molecular informatics.

[11]  E. Smit,et al.  Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: Phase II PHAROS study design. , 2021, Future oncology.

[12]  Joshua M. Dempster,et al.  Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects , 2021, Genome Biology.

[13]  L. Udrescu,et al.  Drug Repurposing Using Modularity Clustering in Drug-Drug Similarity Networks Based on Drug–Gene Interactions , 2021, Pharmaceutics.

[14]  Changzhu Duan,et al.  FDX1 can Impact the Prognosis and Mediate the Metabolism of Lung Adenocarcinoma , 2021, Frontiers in Pharmacology.

[15]  Xiangxiang Zeng,et al.  Drug repositioning based on the heterogeneous information fusion graph convolutional network , 2021, Briefings Bioinform..

[16]  Z. Shao,et al.  Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response , 2021, Journal of Hematology & Oncology.

[17]  Jason M. Sheltzer,et al.  Genome-wide identification and analysis of prognostic features in human cancers , 2022 .

[18]  T. Stockley,et al.  A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. , 2021, Lung cancer.

[19]  Wenyi Wei,et al.  Post-translational regulations of PD-L1/PD-1: Mechanisms and opportunities for combined immunotherapy. , 2021, Seminars in cancer biology.

[20]  T. Sauter,et al.  Topological network measures for drug repositioning , 2020, Briefings Bioinform..

[21]  Mengyun Yang,et al.  Heterogeneous graph inference with matrix completion for computational drug repositioning , 2020, Bioinform..

[22]  Guoqi Li,et al.  Computational drug repositioning based on the relationships between substructure-indication , 2020, Briefings Bioinform..

[23]  A. Goede,et al.  PROMISCUOUS 2.0: a resource for drug-repositioning , 2020, Nucleic Acids Res..

[24]  Wen Zhang,et al.  Predicting drug-disease associations through layer attention graph convolutional network , 2020, Briefings Bioinform..

[25]  Weihua Li,et al.  Drug repositioning by prediction of drug's anatomical therapeutic chemical code via network-based inference approaches , 2020, Briefings Bioinform..

[26]  M. Mayr,et al.  Systems biology in cardiovascular disease: a multiomics approach , 2020, Nature Reviews Cardiology.

[27]  Dan J Stein,et al.  A review of systems biology research of anxiety disorders , 2020, Revista brasileira de psiquiatria.

[28]  C. Klein.  Cancer progression and the invisible phase of metastatic colonization , 2020, Nature Reviews Cancer.

[29]  Xin Huang,et al.  PIMD: An Integrative Approach for Drug Repositioning Using Multiple Characterization Fusion , 2020, Genom. Proteom. Bioinform..

[30]  J. Galon,et al.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy , 2020, Nature Reviews Cancer.

[31]  R. Nussinov,et al.  Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing , 2020, Medicinal research reviews.

[32]  E. Nice,et al.  Overcoming cancer therapeutic bottleneck by drug repurposing , 2020, Signal Transduction and Targeted Therapy.

[33]  Xia Yang,et al.  Multitissue Multiomics Systems Biology to Dissect Complex Diseases. , 2020, Trends in molecular medicine.

[34]  B. Faubert,et al.  Metabolic reprogramming and cancer progression , 2020, Science.

[35]  Paul Bogdan,et al.  Uncovering new drug properties in target-based drug-drug similarity networks , 2020, bioRxiv.

[36]  M. Mckee,et al.  Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. , 2020, JAMA.

[37]  S. Burley,et al.  A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib: a Brief Report. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  Corrado Priami,et al.  A network-based approach to identify deregulated pathways and drug effects in metabolic syndrome , 2019, Nature Communications.

[39]  Jens Nielsen,et al.  Systems biology based drug repositioning for development of cancer therapy. , 2019, Seminars in cancer biology.

[40]  Ying Jiang,et al.  Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities , 2019, Molecular oncology.

[41]  Shuguang Yuan,et al.  Advancing Drug Discovery via Artificial Intelligence. , 2019, Trends in pharmacological sciences.

[42]  B. Cho,et al.  A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. , 2019, Lung cancer.

[43]  Mario Medvedovic,et al.  Predicting mechanism of action of cellular perturbations with pathway activity signatures , 2019, bioRxiv.

[44]  Yaohang Li,et al.  Drug repositioning based on bounded nuclear norm regularization , 2019, Bioinform..

[45]  Emanuel J. V. Gonçalves,et al.  Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens , 2019, Nature.

[46]  Sui Huang,et al.  Aspirin-triggered proresolving mediators stimulate resolution in cancer , 2019, Proceedings of the National Academy of Sciences.

[47]  Hiromasa Yamamoto,et al.  Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations , 2019, Oncology letters.

[48]  Rachel S. Riley,et al.  Delivery technologies for cancer immunotherapy , 2019, Nature Reviews Drug Discovery.

[49]  P. Sanseau,et al.  Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.

[50]  G. Mills,et al.  State-of-the-art strategies for targeting the DNA damage response in cancer , 2018, Nature Reviews Clinical Oncology.

[51]  Stephen T. C. Wong,et al.  Systems biology–based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma , 2018, Science Translational Medicine.

[52]  Nasser Ghadiri,et al.  A review of network‐based approaches to drug repositioning , 2018, Briefings Bioinform..

[53]  L. Bubendorf,et al.  Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers , 2018, Clinical Cancer Research.

[54]  Lili Wang,et al.  Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide , 2018, Oncogene.

[55]  M. Berger,et al.  Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  W. Kaelin,et al.  Common pitfalls in preclinical cancer target validation , 2017, Nature Reviews Cancer.

[57]  Ying Wang,et al.  A randomized phase III study of combining erlotinib with bevacizumab and panitumumab versus erlotinib alone as second-line therapy for Chinese patients with non-small-cell lung cancer. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[58]  W. Walther,et al.  S100A4 in Cancer Metastasis: Wnt Signaling-Driven Interventions for Metastasis Restriction , 2016, Cancers.

[59]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.

[60]  S. Clarke,et al.  Cancer-related inflammation and treatment effectiveness. , 2014, The Lancet. Oncology.

[61]  I. Wistuba,et al.  A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. , 2014, The oncologist.

[62]  E. Lengyel,et al.  WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer , 2014, Oncogene.

[63]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[64]  Jan Budczies,et al.  Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer , 2013, PloS one.

[65]  Jun Zou,et al.  Advanced Systems Biology Methods in Drug Discovery and Translational Biomedicine , 2013, BioMed research international.

[66]  Yong Wang,et al.  Network predicting drug's anatomical therapeutic chemical code , 2013, Bioinform..

[67]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[68]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[69]  Susan Quinn,et al.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Eric B Haura,et al.  Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[72]  Daniel J. Freeman,et al.  Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor , 2009, Molecular Cancer Therapeutics.

[73]  Kenta Nakai,et al.  PrognoScan: a new database for meta-analysis of the prognostic value of genes , 2009, BMC Medical Genomics.

[74]  Kazuko Sakai,et al.  Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway , 2007, Cancer science.

[75]  V. Macaulay,et al.  EGFR Mutations and Lung Cancer , 2005, PLoS Medicine.

[76]  Moshe Talpaz,et al.  Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non–Small Cell Lung Cancer Cells , 2005, Clinical Cancer Research.